ArticleInternational journal of nanomedicine2025
Itraconazole-Loaded Polycaprolactone Nanoparticle Gel for Enhanced Transdermal Delivery: Development, Characterization, and ex vivo Evaluation.
Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Itraconazole (ITZ) is a BCS class II antifungal agent difficult to formulate due to its poor water solubility (<0.2 mmol /mL) and variable oral bioavailability (~55%). This study aimed to develop Polycaprolactone (PCL) nanoparticles to improve their transdermal delivery. Methods: The nanoparticles were prepared using a modified nanoprecipitation method, resulting in ten formulations (F1 to F10). The optimized formulation (F2) was incorporated into a carbopol gel. Characterization included particle size, polydispersity index (PDI), zeta potential, encapsulation efficiency (EE), and in vitro drug release at pH 5.5 and 7.4. Ex vivo permeation, skin irritation, and stability were also evaluated. Results: Formulation F2 (40 mg PCL, 2% Poloxamer 407 showed optimal properties: particle size of 154.6 nm, PDI (0.378), zeta potential (-10.7 ± 5.36 mV), and EE (88.4 ± 1.2%). A pH-dependent sustained release was observed, with 80.41% and 94.34% cumulative release at pH 5.5 and 7.4 over 24 hours, respectively, following Higuchi kinetics (R Conclusion: A promising and biocompatible PCL-based gel was successfully developed, providing an effective approach for enhanced transdermal delivery of ITZ through sustained drug release and improved skin permeability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.